company background image
TRVN logo

Trevena NasdaqCM:TRVN Stock Report

Last Price

US$0.43

Market Cap

US$8.4m

7D

-20.9%

1Y

-43.8%

Updated

25 Mar, 2024

Data

Company Financials +

TRVN Stock Overview

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders.

TRVN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Trevena, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Trevena
Historical stock prices
Current Share PriceUS$0.43
52 Week HighUS$3.28
52 Week LowUS$0.41
Beta1.12
1 Month Change-22.47%
3 Month Change-38.31%
1 Year Change-43.82%
3 Year Change-99.02%
5 Year Change-98.91%
Change since IPO-99.73%

Recent News & Updates

Recent updates

Trevena Q2 2022 Earnings Preview

Aug 10

Trevena slides on $2M preferred stock offering

Jul 29

Trevena (NASDAQ:TRVN) Will Have To Spend Its Cash Wisely

Jul 08
Trevena (NASDAQ:TRVN) Will Have To Spend Its Cash Wisely

Is Trevena (NASDAQ:TRVN) In A Good Position To Deliver On Growth Plans?

Mar 19
Is Trevena (NASDAQ:TRVN) In A Good Position To Deliver On Growth Plans?

Trevena Offers An Enticing Risk-Reward At These Prices

Dec 14

Trevena: Remaining Patient After A Disappointing Q2 Earnings

Aug 17

Trevena announces resumption of NIH-run trial for TRV734 in opioid use disorder

Jun 16

Trevena's OLINVYK Provides One Of The Most Compelling Growth Profiles

May 10

Trevena Investor Presentation - Slideshow

May 08

Trevena (TRVN) Investor Presentation - Slideshow

Nov 16

Trevena: Reaffirming A Buy On OLINVYK DEA Scheduling

Nov 09

DEA classifies Trevena's oliceridine, distribution to start in November

Oct 30

Shareholder Returns

TRVNUS BiotechsUS Market
7D-20.9%0.2%1.3%
1Y-43.8%10.2%29.8%

Return vs Industry: TRVN underperformed the US Biotechs industry which returned 9.8% over the past year.

Return vs Market: TRVN underperformed the US Market which returned 30.4% over the past year.

Price Volatility

Is TRVN's price volatile compared to industry and market?
TRVN volatility
TRVN Average Weekly Movement6.4%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: TRVN's share price has been volatile over the past 3 months.

Volatility Over Time: TRVN's weekly volatility has decreased from 57% to 6% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200735Carrie Bourdowhttps://www.trevena.com

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

Trevena, Inc. Fundamentals Summary

How do Trevena's earnings and revenue compare to its market cap?
TRVN fundamental statistics
Market capUS$8.43m
Earnings (TTM)-US$30.77m
Revenue (TTM)US$3.21m

2.5x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TRVN income statement (TTM)
RevenueUS$3.21m
Cost of RevenueUS$616.00k
Gross ProfitUS$2.59m
Other ExpensesUS$33.36m
Earnings-US$30.77m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.68
Gross Margin80.79%
Net Profit Margin-959.34%
Debt/Equity Ratio835.2%

How did TRVN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.